← Eichor
Study identifier: NCT06473844 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Efficacy of SGLT2 Inhibitors in Adults With Sepsis

Condition: Sepsis · Inflammation · SGLT2 Inhibitors  ·  Sponsor: Hospital Authority, Hong Kong

PhaseNA
Planned participants60
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Goal of this clinical trial is to examine the safety and efficacy of SGLT2 inhibitors on the clinical outcomes in patients with sepsis. Main study outcomes are as follows: (i) Primary objective is to examine the efficacy and safety of SGLT2 inhibitors on clinical outcomes in patients with sepsis. (ii) Secondary objective is to examine the effect of SGLT2 inhibitors on inflammatory markers in patients with sepsis.

This description comes directly from the study's public registry record.

Talk to the study team

Pauline Yeung Ng, MBBS, FHKCP  ·  39103372  ·  pyeungng@hku.hk

Calvin Tam, BSN, RN  ·  07783323202  ·  ct7331@hku.hk

Always discuss trial participation with your own doctor first.

Locations (3)

4/F Main Clinical Block and Trauma Centre, Prince of Wales Hospital, Shatin, New Territories, Hong KongHong Kong, Hong Kong, Hong KongNot Yet Recruiting
Adult Intensive Care Unit, Queen Mary Hospital, 102 Pok Fu Lam Road, Hong KongHong Kong, Hong Kong, Hong KongRecruiting
The University of Hong KongHong Kong, Hong KongRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06473844